Table 1, Table 2 and Table 3 show the top 10 drugs for the year July 2020 – June 2021. The figures are based on PBS and RPBS prescriptions from the date of supply. The figures include prescriptions under the co-payment (non-subsidised).
Table 1. Top 10 PBS/RPBS drugs by DDD/1000 pop/day.
Drug | DDD/1000 pop/day* |
---|---|
1. atorvastatin | 76.22 |
2. rosuvastatin | 66.54 |
3. perindopril | 54.35 |
4. amlodipine | 53.35 |
5. candesartan | 34.56 |
6. telmisartan | 34.55 |
7. irbesartan | 29.36 |
8. setraline | 27.42 |
9. metformin | 26.59 |
10. ramipril | 26.52 |
Table 2. Top 10 PBS/RPBS drugs by prescription counts.
Drug | Prescriptions |
---|---|
1. rosuvastatin | 14,185,361 |
2. atorvastatin | 11,673,109 |
3. pantoprazole | 9,299,295 |
4. esomeprazole | 8,396,611 |
5. perindopril | 6,890,787 |
6. escitalopram | 5,470,158 |
7. metformin | 5,406,768 |
8. sertraline | 5,106,720 |
9. cefalexin | 4,617,588 |
10. amlodipine | 4,475,471 |
Table 3. Top 10 PBS/RPBS drugs by cost to government (does not include rebates).
Drug | Cost to government | Prescriptions |
---|---|---|
1. aflibercept | $443,729,600 | 364,846 |
2. pembrolizumab | $431,701,955 | 49,694 |
3. nivolumab | $402,113,073 | 50,593 |
4. adalimumab | $297,594,138 | 274,986 |
5. denosumab | $263,487,070 | 963,893 |
6. apixaban | $248,455,067 | 3,020,507 |
7. ustekinumab | $246,990,067 | 35,554 |
8. ranibizumab | $221,730,401 | 190,316 |
9. lenalidomide | $221,365,364 | 40,554 |
10. ocrelizumab | $175,644,997 | 10,108 |
DDD defined daily dose
PBS Pharmaceutical Benefits Scheme
RPBS Repatriation Pharmaceutical Benefits Scheme
* DDD/thousand population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people in every thousand Australians are taking the standard dose of a drug every day. DDD includes use in combination products. The calculation is based on ABS 3101.0 – Australian Demographic Statistics for December 2020.
Source: Department of Health, December 2021. © Commonwealth of Australia